Board of Directors

Meet our board of directors.

InfoBionic’s board of directors see the unique value in the MoMe ARC Platform and provide strong industry expertise and guidance to our management team.

Stuart Long
CEO, InfoBionic

Stuart was appointed CEO of InfoBionic in March 2017, underscoring the Company’s commitment to widespread market adoption of its transformative wireless remote patient monitoring platform for chronic disease management. With more than 20 years of experience in the medical device market, Stuart brings a great deal of expertise in achieving rapid commercial growth. Prior to joining InfoBionic, he was CEO at Monarch Medical Systems, LLC, a Charlotte-based, artificial intelligence clinical decision support software provider for insulin dosing calculations, where he oversaw the organizational restructuring of the company.

Prior to Monarch, Stuart served as the global chief marketing and sales officer for Capsule Tech, Inc., a medical device integration and clinical data management system for hospitals and healthcare institutions. During his tenure, he developed and executed a strategic business and product plan that ultimately led to the company’s acquisition by Qualcomm Life, Inc., a subsidiary of Qualcomm, Inc. Prior to Capsule Tech, Stuart worked in executive leadership at Philips Healthcare, overseeing global product management and marketing for their healthcare imaging and informatics group as well as emerging markets in the company’s cardiac monitoring division. Stuart also held executive positions at healthcare IT-focused companies including Agfa Healthcare, AMICAS, FUJIFILM USA and Eastman Kodak in addition to his previous clinical experience of managing acute care, non-invasive cardiology.

Jeremy Ruskin, MD – Board Observer
Director, Cardiac Arrhythmia Service at Massachusetts General Hospital

Dr. Ruskin is a world-renowned cardiologist and electrophysiologist. He is Founder and Director of the Cardiac Arrhythmia Service at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Ruskin received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital in Boston and his fellowship in Cardiovascular Disease at the Massachusetts General Hospital. He received his training in clinical and experimental cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato.

Dr. Ruskin has trained more than 110 fellows in the subspecialty of cardiac arrhythmias over the past 38 years, many of whom are in leadership positions at academic centers throughout the world. In addition, Dr Ruskin is a much sought after speaker at medical conferences and has authored more than 450 original scientific publications, chapters, reviews, and monographs. Dr. Ruskin’s major research interests include: the mechanisms and management of atrial fibrillation; new antiarrhythmic drugs and innovative non-pharmacologic approaches to the treatment of atrial fibrillation; the mechanisms and prevention of ventricular arrhythmias and sudden cardiac death; the role of arrhythmia control devices in the prevention of sudden cardiac death; the proarrhythmic effects of cardiac and non-cardiac drugs and cardiac safety issues in new drug and device development. In 1995, Dr. Ruskin founded the Annual International Atrial Fibrillation Symposium which he has directed since its inception and is the largest and longest running free-standing academic meeting on atrial fibrillation worldwide. Dr. Ruskin also maintains an active regional, national and international referral practice in the field of cardiac arrhythmias and electrophysiology and is recognized annually in Best Doctors in Boston and Best Doctors in America. He is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology and the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award.

Adrian Steckel
CEO, The VOID

Adrian is the Chief Executive Officer at The VOID, an immersive virtual reality entertainment provider, where he is responsible for overseeing the company’s growth. Since 199, he has been building companies from the ground up and working to enable voice and data communications in countries around the world.

Adrian previously served as CEO of OneWeb, a London-based global communications company, and lusacell, a very successful mobile carrier in Mexico, which sold to AT&T in 2015. He also led the buildout and operations of the fiber backbones in both Colombia and Peru in cooperation with their respective governments and during his time as CFO at TV Azteca, he took the company public on the New York Stock Exchange (NYSE).

Follow Adrian at: @adriansteckel

Eric C. Salzman
CEO, Safeguard Scientifics

Eric has more than 25 years of experience as a strategic executive, private equity investor, advisor, and board member working with public and private growth companies to drive business transformation, develop and implement strategic operating plans, and manage corporate finance and M&A transactions.

Eric joined Safeguard as its Chief Restructuring Officer in April 2020 and is responsible for developing and executing its strategy, managing day-to-day operations, and engaging with public shareholders. Eric serves as Safeguard’s board member at InfoBionic, Inc. and as a board observer at MediaMath, Inc.

Eric has extensive experience helping companies manage through different stages of growth and maturation. He has served as a board member and advisor to portfolio companies of several public and private technology companies representing funds including Ares, Athyrium, Blackstone/GSO, Carlyle, and KKR. Eric currently serves as an independent direct on the board of publicly traded 8×8, Inc., where he is Chairman of the Compensation Committee, and privately owned SolAero Technologies, Inc, where he is Chairman of the Board.

Eric spent nearly ten years employed by Lehman Brothers as a Managing Director in the Private

Caleb Winder Managing Director, Excel Venture Management

Caleb has nearly 20 years of operating, startup, and financing experience in life science and healthcare companies. He plays an instrumental role in sourcing and structuring deals and works closely with portfolio companies to form strategic partnerships and to develop commercialization and marketing strategies. He currently (or formerly) represents Excel as a Board Director or Observer at Aventura, InfoBionic, Molecular Templates, ShapeUp, Saladax Biomedical, and MedVentive (sold to McKesson). Prior to joining Excel, Caleb was a Principal at Biotechonomy, where he financed and managed several entrepreneurial ventures, including Synthetic Genomics, where he was also the Director of Finance, BioTrove (sold to Life Technologies), Biocius (sold to Agilent Technologies), and Xcellerex (sold to GE).

Prior to becoming a venture capitalist, Caleb was an award winning sales and marketing executive at medical device and diagnostics companies. He received his M.B.A. from Babson College, magna cum laude, where he was a Babson Fellow in the Center for Technology Enterprise. He received a B.A. in Biology with a minor in Economics from Colby College.

Hamid Tabatabaie
CEO, CodaMetrix

Hamid Tabatabaie is the CEO of CodaMetrix, a technology company solving some of the more challenging problems in healthcare, using AI technology to automate the functions that burden doctors. Previously, Hamid founded lifeIMAGE, the most utilized cloud-based service for exchange of diagnostic imaging information. He was the CEO and an advisor for lifeIMAGE. During his 30-year career in health information technology Hamid has served as the chief executive of 4 successful startups. For the past fifteen years, he has been at the forefront of innovation in medical imaging informatics. Prior to lifeIMAGE, he led AMICAS, a pioneer in use of the web to automate the processes and the business of diagnostic imaging.

Following a personal experience as a caregiver frustrated with the inability to share medical records across various healthcare settings, he founded lifeIMAGE to develop a better way for physicians to share patients’ imaging records. Now, 9 million records containing 2 billion images have been exchanged on lifeIMAGE. Many of the nation’s renowned hospitals and academic medical centers use the network to expedite care, triage referrals, and avoid duplication of unnecessary imaging exams. The network is simultaneously used to share medical images and associated reports with patients.

Dennis Depenbusch – Board Observer
Corporate Venture Capital, BlueCross and BlueShield of Kansas

Dennis is an entrepreneurial leader who believes that growing a business with people who love to win requires passionate certainty, diligent pursuit, and disciplined performance. Today, he is responsible for the direction, coordination, evaluation, and management in developing and leading strategic investment from a $50 million venture capital fund for BlueCross and BlueShield of Kansas.

Dennis utilizes 25+ years of entrepreneurial experience to help create, build, and guide high-growth teams and enterprises. He is focused on collaboratively designing and networking to execute strategic plans that deliver revenue and provide return for investors and owners.

Andrew Cole – Board Observer
Financial Reporting Manager, Blue Cross Blue Shield of Massachusetts

Andrew brings more than 14 years of expertise in accounting and business administration. He currently serves as Financial Reporting Manager for Blue Cross Blue Shield of Massachusetts, where he has been responsible for managing accounting and reporting as well as aiding in strategic decision making on investments.

Previously, Andrew held roles in accounting and business analytics for Keurig Green Mountain, Inc.